Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 9/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.34 |
| ▸ | PDE4A | P27815 | 5/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717105 | 0.93 | SLC5A7 (0.37) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23717442 | 0.91 | SLC5A7 (0.33) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23717274 | 0.90 | POLB (0.37) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23683775 | 0.90 | SLC5A7 (0.36) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23717285 | 0.89 | PDE4D (0.36) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23717271 | 0.88 | AR (0.34) | SLC5A7 | |
| SCHEMBL23717286 | 0.88 | SLC5A7 (0.35) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23700633 | 0.84 | CFTR (0.34) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23700636 | 0.84 | CFTR (0.34) | SLC5A7EPHX2PDE4DPDE4APDE4B | |
| SCHEMBL23700635 | 0.84 | CFTR (0.34) | SLC5A7EPHX2PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | SLC5A7 2873/4885EPHX2 833/4885PDE4D 1685/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | SLC5A7 2873/4885EPHX2 833/4885PDE4D 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.